Postdiagnosis aspirin use reduces risk of dying from colorectal cancer

Regular use of aspirin after colorectal cancer diagnosis may reduce the risk of cancer death, report Harvard researchers at Massachusetts General Hospital (MGH), Dana-Farber Cancer Institute (DFCI) and Brigham and Women’s Hospital.  In today's edition of the Journal of the American Medical Association, the study’s authors also find that the aspirin-associated survival advantage was seen primarily in patients with tumors expressing the COXread more

Read the whole article on Harvard Science

More from Harvard Science